Cytokinetics

San Francisco, United States Founded: 1997 • Age: 29 yrs Listed
Muscle activators are developed for debilitating diseases.

About Cytokinetics

Cytokinetics is a publicly listed company based in San Francisco (United States) founded in 1997. Muscle activators are developed for debilitating diseases. Cytokinetics has raised $60 million across 11 funding rounds from investors including Morgan Stanley, Duke University and HHS. The company has 498 employees. Its website cytokinetics.com draws about 25 thousand monthly visits. Cytokinetics offers products and services including Cardiac Myosin Inhibitors and Muscle Activators. Its focus areas include Life Sciences, Orthopedics, Drugs and Muscle Disorders. Its competitors include AskBio, BioAge Labs and Solid Biosciences; 3 of its 3 listed competitors have raised funding.

Company details

Cytokinetics was founded in 1997 and is headquartered in San Francisco, United States. Operations focus on the biotechnology sector, where muscle activators are developed as treatments for conditions such as heart failure and spinal muscular atrophy. The drug pipeline includes omecamtiv mecarbil, a cardiac myosin activator investigated in collaboration with Amgen, and CK-2127107, a skeletal muscle troponin activator targeted at SMA patients.

  • Headquarters San Francisco, United States
  • Employees 498
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website cytokinetics.com
  • Social LinkedIn X Facebook YouTube
  • Legal Name Cytokinetics, Incorporated
Operational Areas
Key Metrics
  • Annual Revenue
    $88.04 M (USD)
    376.56
    as on Dec 31, 2025
  • Net Profit
    -$784.96 M (USD)
    -33.15
    as on Dec 31, 2025
  • EBITDA
    -$602.13 M (USD)
    -14.32
    as on Dec 31, 2025
  • Total Equity Funding
    $60M (USD)

    in 11 rounds

  • Latest Funding Round
    $450M (USD), Post-IPO

    Jul 2022

  • Investors
  • Employee Count
    498

Products & Services of Cytokinetics

Cytokinetics offers a comprehensive portfolio of products and services, including Cardiac Myosin Inhibitors and Muscle Activators.

Cardiac Myosin Inhibitors
Drug Development

Inhibitors targeting heart failure and hypertrophic cardiomyopathy treatments

Muscle Activators
Drug Development

Activators for neuromuscular disease management and function improvement

Apps and channels of Cytokinetics

its YouTube channel Cytokinetics has 513 subscribers and 30 videos.

Cytokinetics
YouTube 513 subscribers 30 videos Science & Technology
Open channel

Videos from Cytokinetics

The most watched videos on Cytokinetics's YouTube channel, Cytokinetics (513 subscribers). Click a video to play it here.

Behind ALS: Follow the Muse, The Lindsay Abromaitis-Smith Story
80.8K views
Trailer - Fortitude on the Frontiers of Science
32.4K views
Behind ALS: Soldier On, The Chuck Schretzman Story
13.8K views
Muscle Activation Made Simple
9.9K views

More on Cytokinetics.

Funding Insights of Cytokinetics

Cytokinetics has successfully raised a total of $60M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $450 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $60M
  • Total Rounds 11
  • Last Round Post-IPO β€” $450M
  • First Round $20M

    (Oct 1999)

  • Investors Count 6

Latest 10 of 11 funding rounds of Cytokinetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2022$450MPost-IPO––
–
Jul 2020Post-IPO––
–
Nov 2019$138MPost-IPO––
–
May 2017$75MPost-IPO––
Jun 2013$10MPost-IPO––
Jul 2010$3.48MGrant––
Jul 2010$3.48MGrant––
Sep 2008$99,992Grant––
Sep 2008$99,992Grant––
Apr 2003$40MSeries C––
–
Valuation history

6 investors in total: 6 institutional.

Investors in Cytokinetics

Cytokinetics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Morgan Stanley, Duke University and HHS.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital investments are facilitated by Amgen-backed entity.
amgenbd.comThousand Oaks, United States
vulcanventuresinvestments.com
Early-stage US investments in technology and offline sectors are targeted.
srfunds.comDallas, United States
Wealth management, investment advisory, and financial services are provided.
1935morganstanley.comNew York, United States
Public health and human services are overseen by HHS.
1953hhs.gov
Multiple courses and degrees across diversified streams are offered.
1838duke.eduUnited States
Premium access

Investor details for Cytokinetics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Cytokinetics

299 people are tracked at Cytokinetics (165 in leadership, 20 in board & advisors, 114 in team); the tracked headcount is 498.

NameRoleGroup
Jonathan Kaltman
Senior Medical Director, Clinical Research CardiovascularLeadership
Prodromos Anthopoulos
VP, Head of Medical Affairs, EuropeLeadership
Robert Blum
President & CEOLeadership
Colleen Healy
Director, Professional Society EngagementLeadership
Amy Diehl
Director, Market Development LeadLeadership
Norma Tom
VP, Chemistry, Manufacturing and ControlLeadership
Jeff Lotz
VP, Sales and OperationsLeadership
Armina Fortuna Riethmuller
Director, Drug Safety Operations, Compliance Europe And Deputy EU QPPVLeadership
Daryl Luey
Director, Quality AssuranceLeadership
Andrew Callos
EVP, Chief Commercial OfficerLeadership
John Faurescu
Vice President, Head Of Legal & Corporate SecretaryLeadership
Boris Velinov
Global Marketing DirectorLeadership
Amish Patel
Associate Director, Drug Safety PhysicianLeadership
Stuart Kupfer
SVP, Chief Medical OfficerLeadership
Spencer Y.
Director, Regulatory Project ManagementLeadership
Rose Ann P.
Associate Director Human ResourcesLeadership
Amy Wang
Director, Tech Ops CMC AnalyticalLeadership
Bob Wegner
Director, Marketing Capabilities And OperationsLeadership
Blanca B.
Associate Director Of Patient Support ServicesLeadership
Camelia Dumitrescu
Head Of Drug Safety And PharmacovigilanceLeadership

279 more people are available in the full profile.

Premium access

Complete people profiles for Cytokinetics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Cytokinetics

Cytokinetics is a publicly listed company on the NASDAQ with ticker symbol CYTK in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date29 Apr 2004
  • Listed onNASDAQ: CYTK
  • Listed entityCytokinetics, Incorporated
  • Exchange sectorHealth technology
  • ISINUS23282W6057
  • Share price$61.62 (-1.86% on the day) · 2026-10-13
  • Market capitalisation$8.57B
  • EPS (diluted, trailing year)$-7.22
  • Volume (last session)1,935,973

Financials of Cytokinetics

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$88.0M-$785.0M-$602.1M
2024$18.5M-$589.5M-$526.7M
2023$7.5M-$526.2M-$484.3M
2022$94.6M-$388.9M-$315.8M
2021$70.4M-$215.3M-$176.7M
Premium access

Detailed financial statements for Cytokinetics

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Cytokinetics

4 dated milestones of Cytokinetics across 25 years, from founding to its latest funding, stage changes and deals.

  1. Founded Cytokinetics is founded.
  2. Funding First funding round of $20.0M.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $450.0M.

Competitors of Cytokinetics

Cytokinetics has 3 listed competitors in our database, 3 of them funded. They include AskBio, BioAge Labs and Solid Biosciences.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
askbio.com2001Durham, United States$235M
Gene and protein therapies are developed for treating various diseases.
bioagelabs.com2015Vallejo, United States$293.9M43
Bioinformatics platform is provided for biomarkers and drug discovery.
solidbio.com2014Cambridge, United States$92.5M101
Gene therapy platform for Duchenne muscular dystrophy is developed.
Premium access

Detailed competitors of Cytokinetics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Cytokinetics

The website of Cytokinetics (cytokinetics.com) receives about 25.3K visits a month and ranks #1,072,700 among all websites worldwide, #1,325 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    25.3K

    ▲ 5.8% vs previous month

  • Unique visitors
    13.4K

    per month

  • Global rank
    #1,072,700

    among all websites

  • Category rank
    #1,325

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Cytokinetics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
denalitherapeutics.com
100%
26.9K#914,827View details
cytori.com
100%
1.3K#12,091,883View details
mazetx.com
99%
9.2K#2,405,150View details
ctibiopharma.com
94%
View details
lenz-tx.com
93%
20.1K#1,219,956View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 11 similar websites and full traffic analytics for Cytokinetics

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 11 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Orthopedics

3 companies that operate in the same segment as Cytokinetics (Orthopedics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Provider of high-frequency spinal cord stimulation implants
2006Menlo Park, California, United StatesUSD 154.1 MUSD 353.08 M1,215
Developer of therapies for the treatment of musculoskeletal disorders
2007Woburn, Massachusetts, United StatesUSD 62 MUSD 85.55 M692
Antibody-siRNA complexes are developed for cancer treatment.
2012San Diego, California, United StatesUSD 142.54 MUSD 10.9 M391
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cytokinetics

Premium access

Complete news archive for Cytokinetics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cytokinetics

Cytokinetics was founded in 1997 and raised its 1st funding round 2 years after it was founded.

Cytokinetics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Cytokinetics is a funded company, having raised a total of $60M across 11 funding rounds to date. The company's 1st funding round was a Series C of $40M, raised on Oct 1999.

Cytokinetics has 498 employees.

Annual revenue of Cytokinetics is $88.04M as on Dec 31, 2025.

Cytokinetics was founded in 1997 and is headquartered in San Francisco, United States. Operations focus on the biotechnology sector, where muscle activators are developed as treatments for conditions such as heart failure and spinal muscular atrophy. The drug pipeline includes omecamtiv mecarbil, a cardiac myosin activator investigated in collaboration with Amgen, and CK-2127107, a skeletal muscle troponin activator targeted at SMA patients.

Cytokinetics's top competitors include AskBio, Solid Biosciences and BioAge Labs.

Cytokinetics offers Cardiac Myosin Inhibitors and Muscle Activators.

Yes, Cytokinetics is publicly traded on NASDAQ under the ticker symbol CYTK.

Cytokinetics has 6 investors. Key investors include Morgan Stanley, Duke University, HHS, Amgen Business Development, and Vulcanventuresinvestments.com.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available